165 related articles for article (PubMed ID: 31221437)
1. Mast cells: A key component in the pathogenesis of Neuromyelitis Optica Spectrum Disorder?
Medeiros WLG; Bandeira IP; Franzoi AEA; Brandão WN; Santos Durão ACCD; Gonçalves MVM
Immunobiology; 2019 Sep; 224(5):706-709. PubMed ID: 31221437
[TBL] [Abstract][Full Text] [Related]
2. Th17 cells in neuromyelitis optica spectrum disorder: a review.
Lin J; Li X; Xia J
Int J Neurosci; 2016 Dec; 126(12):1051-60. PubMed ID: 26954363
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series.
Bernard-Valnet R; Cobo-Calvo A; Siegfried A; Marasescu R; Bonnan M; Ballan G; Ellie E; Bauer J; Uro-Coste E; Marignier R; Brassat D
Mult Scler Relat Disord; 2019 Jun; 31():97-100. PubMed ID: 30954932
[TBL] [Abstract][Full Text] [Related]
4. Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder.
Kong BS; Kim Y; Kim GY; Hyun JW; Kim SH; Jeong A; Kim HJ
J Neuroinflammation; 2017 Sep; 14(1):191. PubMed ID: 28946890
[TBL] [Abstract][Full Text] [Related]
5. Correlation between serum levels of endothelin-1 and disease severity in patients with neuromyelitis optica spectrum disorders.
Yi M; Liu MQ; Chou LS; Jiang SM; Zhang LJ; Huang CN; Wang N; Zhang QX; Yang L
Immunobiology; 2020 May; 225(3):151959. PubMed ID: 32517881
[TBL] [Abstract][Full Text] [Related]
6. Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.
Dos Passos GR; Sato DK; Becker J; Fujihara K
Mediators Inflamm; 2016; 2016():5314541. PubMed ID: 26941483
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
Wu Y; Zhong L; Geng J
Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review.
Shahmohammadi S; Doosti R; Shahmohammadi A; Mohammadianinejad SE; Sahraian MA; Azimi AR; Harirchian MH; Asgari N; Naser Moghadasi A
Mult Scler Relat Disord; 2019 Jan; 27():350-363. PubMed ID: 30476871
[TBL] [Abstract][Full Text] [Related]
9. Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder.
Kong Y; Li HD; Wang D; Gao X; Yang C; Li M; Chang T; Liu Q
FASEB J; 2021 Nov; 35(11):e21856. PubMed ID: 34606651
[TBL] [Abstract][Full Text] [Related]
10. Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.
Rosales D; Kister I
Curr Allergy Asthma Rep; 2016 Jun; 16(6):42. PubMed ID: 27167974
[TBL] [Abstract][Full Text] [Related]
11. Foxp3+ regulatory T cells expression in neuromyelitis optica spectrum disorders.
Brill L; Lavon I; Vaknin-Dembinsky A
Mult Scler Relat Disord; 2019 May; 30():114-118. PubMed ID: 30771576
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
Lin J; Xue B; Li X; Xia J
Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606
[TBL] [Abstract][Full Text] [Related]
13. Anti-NMDAR encephalitis followed by seropositive neuromyelitis optica spectrum disorder: A case report and literature review.
Ran Y; Wang L; Zhang F; Ao R; Dong Z; Yu S
Clin Neurol Neurosurg; 2017 Apr; 155():75-82. PubMed ID: 28282627
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder.
Yamashita K; Kinoshita M; Miyamoto K; Namba A; Shimizu M; Koda T; Sugimoto T; Mori Y; Yoshioka Y; Nakatsuji Y; Kumanogoh A; Kusunoki S; Mochizuki H; Okuno T
J Neuroinflammation; 2018 Apr; 15(1):125. PubMed ID: 29703264
[TBL] [Abstract][Full Text] [Related]
15. The role and mechanisms of Microglia in Neuromyelitis Optica Spectrum Disorders.
Li W; Liu J; Tan W; Zhou Y
Int J Med Sci; 2021; 18(14):3059-3065. PubMed ID: 34400876
[TBL] [Abstract][Full Text] [Related]
16. Low-Density Granulocytes Are a Novel Immunopathological Feature in Both Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.
Ostendorf L; Mothes R; van Koppen S; Lindquist RL; Bellmann-Strobl J; Asseyer S; Ruprecht K; Alexander T; Niesner RA; Hauser AE; Paul F; Radbruch H
Front Immunol; 2019; 10():2725. PubMed ID: 31849944
[No Abstract] [Full Text] [Related]
17. Peripheral Blood Th1/Th17 Immune Cell Shift is Associated with Disease Activity and Severity of AQP4 Antibody Sero-Positive Neuromyelitis Optica Spectrum Disorder.
Cao F; Wang Y; Wei R; Li C; Cheng Y; Zhou Y; Jin T; Zhang H; Lin L; Xu B
Neuropsychiatr Dis Treat; 2023; 19():2413-2421. PubMed ID: 37965529
[TBL] [Abstract][Full Text] [Related]
18. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
[TBL] [Abstract][Full Text] [Related]
19. Immunopathogenesis of neuromyelitis optica.
Levy M; Wildemann B; Jarius S; Orellano B; Sasidharan S; Weber MS; Stuve O
Adv Immunol; 2014; 121():213-42. PubMed ID: 24388217
[TBL] [Abstract][Full Text] [Related]
20. [Neuromyelitis optica and neuromyelitis optica spectrum disorders].
Simaniv TO; Vasiliev AV; Askarova LS; Zakharova MN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):35-48. PubMed ID: 31934987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
